The first shot that protects all infants against respiratory syncytial virus, or RSV, won the backing of the Centers for Disease Control and Prevention on Thursday.
RSV is the leading cause of hospitalization among infants in the U.S. The shot, branded under the name Beyfortus, provides families with a simple option to protect their babies during the respiratory virus season.
The CDC’s panel of independent advisors unanimously recommended AstraZeneca and Sanofi’s shot, also called nirsevimab, after reviewing the data in an hourslong meeting Thursday afternoon.